Bausch + Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily d… Read more
Bausch + Lomb Corp (BLCO) - Net Assets
Latest net assets as of September 2025: $6.50 Billion USD
Based on the latest financial reports, Bausch + Lomb Corp (BLCO) has net assets worth $6.50 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.83 Billion) and total liabilities ($7.33 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.50 Billion |
| % of Total Assets | 46.99% |
| Annual Growth Rate | -8.19% |
| 5-Year Change | -34.48% |
| 10-Year Change | N/A |
| Growth Volatility | 8.59 |
Bausch + Lomb Corp - Net Assets Trend (2019–2024)
This chart illustrates how Bausch + Lomb Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bausch + Lomb Corp (2019–2024)
The table below shows the annual net assets of Bausch + Lomb Corp from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.54 Billion | -5.43% |
| 2023-12-31 | $6.92 Billion | -2.55% |
| 2022-12-31 | $7.10 Billion | -24.47% |
| 2021-12-31 | $9.40 Billion | -5.87% |
| 2020-12-31 | $9.99 Billion | -0.44% |
| 2019-12-31 | $10.03 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bausch + Lomb Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 57100000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-1.39 Billion | -21.40% |
| Other Components | $8.43 Billion | 130.22% |
| Total Equity | $6.47 Billion | 100.00% |
Bausch + Lomb Corp Competitors by Market Cap
The table below lists competitors of Bausch + Lomb Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Uxin Ltd
NASDAQ:UXIN
|
$713.35 Million |
|
Nippon Paper Industries Co. Ltd
F:9NI
|
$713.41 Million |
|
Greencore Group plc
PINK:GNCGF
|
$713.42 Million |
|
Zhenjiang Dongfang Electric Heat
SHE:300217
|
$713.56 Million |
|
Yueyang Forest & Paper Co Ltd
SHG:600963
|
$712.65 Million |
|
Shenzhen China Micro Semicon Co. Ltd. A
SHG:688380
|
$712.58 Million |
|
Japfa Comfeed Indonesia Tbk
JK:JPFA
|
$712.40 Million |
|
Metropolitan Bank Holding
NYSE:MCB
|
$712.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bausch + Lomb Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,850,000,000 to 6,473,000,000, a change of -377,000,000 (-5.5%).
- Net loss of 317,000,000 reduced equity.
- Share repurchases of 12,000,000 reduced equity.
- Other comprehensive income decreased equity by 140,000,000.
- Other factors increased equity by 92,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-317.00 Million | -4.9% |
| Share Repurchases | $12.00 Million | -0.19% |
| Other Comprehensive Income | $-140.00 Million | -2.16% |
| Other Changes | $92.00 Million | +1.42% |
| Total Change | $- | -5.50% |
Book Value vs Market Value Analysis
This analysis compares Bausch + Lomb Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.91x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.59x to 0.91x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $28.45 | $16.71 | x |
| 2020-12-31 | $28.34 | $16.71 | x |
| 2021-12-31 | $26.65 | $16.71 | x |
| 2022-12-31 | $20.09 | $16.71 | x |
| 2023-12-31 | $19.54 | $16.71 | x |
| 2024-12-31 | $18.40 | $16.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bausch + Lomb Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.62%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 2.08x
- Recent ROE (-4.90%) is below the historical average (-0.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 2.99% | 7.89% | 0.33x | 1.15x | $-697.90 Million |
| 2020 | -0.18% | -0.53% | 0.30x | 1.14x | $-1.01 Billion |
| 2021 | 1.95% | 4.83% | 0.35x | 1.16x | $-750.90 Million |
| 2022 | 0.09% | 0.16% | 0.34x | 1.58x | $-697.30 Million |
| 2023 | -3.80% | -6.27% | 0.31x | 1.96x | $-945.00 Million |
| 2024 | -4.90% | -6.62% | 0.36x | 2.08x | $-964.30 Million |
Industry Comparison
This section compares Bausch + Lomb Corp's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bausch + Lomb Corp (BLCO) | $6.50 Billion | 2.99% | 1.13x | $713.24 Million |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |